Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Neldaleucel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Marker Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Marker and Cellipont Partner to Manufacture MT-601 T Cell Therapy for Lymphoma
Details : Through the collaboration, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for Marker’s APOLLO study.
Product Name : MT-601
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 17, 2025
Lead Product(s) : Neldaleucel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Marker Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : STM-01
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Secretome Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Cellipont, Secretome Partner for cGMP Manufacturing for STM-01 Lead Asset
Details : Under this partnership, Cellipont will provide technology transfer, analytical method transfer, and cGMP manufacturing for the STM-01 for treating Heart Failure With Preserved Ejection Fraction.
Product Name : STM-01
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : STM-01
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Secretome Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : MGB-001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Mongoose Bio
Deal Size : Undisclosed
Deal Type : Agreement
Cellipont Bioservices, Mongoose Bio Partner to Advance MGB-001
Details : The agreement aims for the technology transfer, process development, and cGMP manufacture of Mongoose's autologous MGB-001 TCR-T cell therapy program.
Product Name : MGB-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 10, 2024
Lead Product(s) : MGB-001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Mongoose Bio
Deal Size : Undisclosed
Deal Type : Agreement